Sera's PreTRM wins a second Medicaid state as the company starts its EU CE Mark route

What happened

Sera Prognostics reports that Florida has become the second state Medicaid programme to cover its PreTRM preterm birth risk test. The company disclosed this in an exhibit to a US securities filing. In the same announcement it said it has begun EU certification for a kit-based version of the test.

The record is thin on detail. It does not say what conditions Florida attaches to coverage, which patients are eligible, what the payment rate is or when coverage starts. It also does not name the first Medicaid state in the company's own wording, specify the EU device class, or say which route or notified body the CE Mark process involves. This is a company-reported development, and we have not seen a payer-side statement.

Why a second Medicaid state matters

Medicaid is run state by state, so each coverage decision is its own negotiation and its own evidence review. Going from one covering state to two does not create a national position. It does show that the case for the test has now convinced more than one state programme, which is the kind of precedent that market access teams for diagnostics look for when approaching the next payer.

The limits are just as important. Without the coverage criteria or rates, it is not possible to say how broad or how financially meaningful the Florida decision is. Teams benchmarking comparable prenatal or risk-stratification tests should treat the announcement as a signal to monitor. They should not treat it as a pricing reference until the policy text is public.

The EU step: CE Mark for a kit-based version

The EU move is a different kind of milestone. A CE Mark is a condition for placing a diagnostic on the EU market. It is not reimbursement, and it does not guarantee that any national payer or health technology assessment body will pay for the product. In the EU, in vitro diagnostics are regulated under the IVDR, where higher-risk classes generally require notified body involvement. The records do not say which class applies here.

The reference to a kit-based version matters commercially. A kit generally allows testing outside a single central laboratory, which changes the supply model, the quality system obligations and the cost structure. Whether that model suits the way European health systems commission and fund testing is an open question. The records give no timeline for certification and no information on European pricing or reimbursement plans.

Reading it alongside the day's payment news

Two other records from the same day give context for payment policy, though they do not bear directly on this test. CMS has finalised the 2027 Medicare Physician Fee Schedule rule and the CY2027 hospital outpatient and ambulatory surgical centre rule (CMS-1850-F). Both take effect from 2027. Provision-level detail was not available in the records we reviewed. Medicare and Medicaid are separate programmes, so these rules do not determine Florida's approach, but US diagnostics and services teams will want to see how the new payment policies affect their wider reimbursement environment.

In Italy, AIFA updated its monitoring registries. From 4 November it added Ranluspec (ranibizumab) to the simplified multi-drug anti-VEGF form for four eye-disease indications. It also updated the XOSPATA (gilteritinib) registry so that prior quizartinib no longer rules out use in relapsed or refractory FLT3-mutated AML. These concern medicines, not diagnostics. They do illustrate how European access is often shaped by operational conditions such as registry eligibility criteria, not by regulatory authorisation alone. Companies entering Europe with a new technology should expect similar fine print at national level.

What to watch

On the US side, watch for the published Florida coverage policy, including eligibility criteria, documentation requirements and the rate, and for whether further state programmes follow. On the EU side, watch for confirmation of the certification pathway and timeline, and for any signs of how national payers or HTA bodies will view a kit-based format. Whether clinical or economic evidence is being prepared for those audiences is not stated in the records.